The purpose of this study is to test whether eating earlier in the day and/or timed light therapy can improve blood sugar in people with type 2 diabetes. This study will also test whether these treatments improve other aspects of health, including the circadian (biological) clock, sleep, weight, body composition, cardiovascular health, quality of life, and mood.
The circadian system is strongly linked to type 2 diabetes. Adults with type 2 diabetes have circadian rhythms that are both weakened and mistimed. Weak rhythms may be due to insufficient bright light exposure during the daytime, irregular meal timing, or grazing on food throughout the day. Mistiming may be due to ill-timed food intake or light exposure-such as eating later in the day or light exposure at night-which causes central and peripheral circadian clocks within the body to become out of sync (circadian misalignment). This circadian misalignment impairs glucose metabolism: data now show that eating late in the day and light exposure at night rapidly elevate glucose (blood sugar) and insulin levels in humans within days. Conversely, well-timed food intake and light exposure appear to improve glycemic (blood sugar) control, circadian rhythms, and several other aspects of health. This study will test the health effects of eating early in the daytime (early time-restricted feeding; early TRF) and timed light therapy in adults with type 2 diabetes. The study will test the following aims: 1. Determine whether early TRF and/or timed light therapy improve glycemic control 2. (a) Determine how early TRF and/or timed light therapy affect the central and peripheral circadian clocks and (b) determine which patients benefit the most from circadian-based therapies 3. Determine whether early TRF and/or timed light therapy improve sleep, body weight, body composition, cardiovascular risk factors, quality of life, and psychological health. Approximately 344 veterans and civilians aged 30-80 with insulin-independent type 2 diabetes will be randomized to the following 2 x 2 study design: 1. No change in eating or light exposure habits 2. Early TRF 3. Timed light therapy 4. Early TRF and timed light therapy Participants will be asked to follow their assigned treatment for 16 weeks and then be followed up for an additional eight months (1 year in total). Baseline and post-intervention testing will be conducted during a 38-hour inpatient (hospital) stay. Testing will involve three 3-hour meal tolerance tests to determine insulin sensitivity and secretion; 24-hour measurement of glucose, insulin, and C-peptide levels; 24-hour measurement of cortisol and melatonin to measure the phase and amplitude of the central clock; and a constant glucose infusion to determine the phase and amplitude of the effective glycemic ("peripheral") circadian clock. Sleep, weight loss, body composition, and cardiovascular risk factors will also be measured, and questionnaires and an interview will be administered to determine improvements in quality of life and psychological health. Note: Pre-registered primary and secondary outcomes are listed below. Pre-registered tertiary outcomes appear in the study protocol, which will be uploaded to this website.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
344
Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
Participants will not change their light exposure habits.
Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.
Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
University of Alabama at Birmingham; Birmingham Veterans Affairs Medical Center
Birmingham, Alabama, United States
24-hour glucose levels
Time-weighted mean, fasting, peak, standard deviation, and excursion (maximum - minimum) values (mg/dl)
Time frame: 16 weeks
24-hour insulin levels
Time-weighted mean, fasting, peak, standard deviation, and excursion values (mU/l)
Time frame: 16 weeks
24-hour C-peptide levels
Time-weighted mean, fasting, peak, standard deviation, and excursion values (pmol/l). This is also a proxy for total 24-hour insulin secretion.
Time frame: 16 weeks
Hemoglobin A1C
%
Time frame: 16 weeks
Insulin sensitivity
Insulin sensitivity (dl/kg/min/μU/ml) during three identical meal tolerance tests, as measured by the Oral Minimal Model. The individual, mean, and excursion values, and time of the peak value will also be calculated.
Time frame: 16 weeks
Beta-cell responsivity index (a measure of beta-cell function)
Beta-cell responsivity during three identical meal tolerance tests, as measured by the Oral Minimal Model. The individual, mean, and excursion values, and time of the peak value will also be calculated.
Time frame: 16 weeks
Insulin secretion
Insulin secretion (mU) across three identical meal tolerance tests, as measured by the Oral Minimal Model. The individual, mean, and excursion values, and time of the peak value will also be calculated.
Time frame: 16 weeks
Melatonin Amplitude
Peak value (pg/mL)
Time frame: 16 weeks
Cortisol Amplitude
Amplitude (μg/dl)
Time frame: 16 weeks
Melatonin Phase
Clock time of dim light melatonin onset (DLMO)
Time frame: 16 weeks
Cortisol Phase
Clock time of cortisol phase
Time frame: 16 weeks
Glycemic ("Peripheral") Rhythm Amplitude
Amplitude or diurnal variation in glucose levels (mg/dl) during a constant glucose infusion procedure
Time frame: 16 weeks
Glycemic ("Peripheral") Rhythm Phase
Time of day that glucose levels experience a nadir during a constant glucose infusion procedure
Time frame: 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.